TIGIT and acute myeloid leukemia: To further analyze correlations between TIGIT+Foxp3+ and DNAM-1+Foxp3+ γδ T cells, clinical outcome, and OS, we next divided the subsets into high-expression and low-expression groups based on median proportions for 27 de novo AML patients and assessed their associations.